Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 1
1973 1
1980 2
1981 3
1982 3
1985 1
2002 1
2003 1
2007 5
2008 4
2009 3
2010 5
2011 4
2013 5
2014 8
2015 11
2016 8
2017 6
2018 10
2019 9
2020 9
2021 5
2022 13
2023 8
2024 10

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

116 results

Results by year

Filters applied: . Clear all
Page 1
Mycoplasma pneumoniae: gone forever?
Meyer Sauteur PM, Beeton ML; ESGMAC the ESGMAC MAPS study group. Meyer Sauteur PM, et al. Lancet Microbe. 2023 Oct;4(10):e763. doi: 10.1016/S2666-5247(23)00182-9. Epub 2023 Jun 29. Lancet Microbe. 2023. PMID: 37393927 Free article. No abstract available.
Mycoplasma pneumoniae: delayed re-emergence after COVID-19 pandemic restrictions.
Meyer Sauteur PM, Beeton ML; European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Mycoplasma and Chlamydia Infections (ESGMAC), and the ESGMAC Mycoplasma pneumoniae Surveillance (MAPS) study group. Meyer Sauteur PM, et al. Lancet Microbe. 2024 Feb;5(2):e100-e101. doi: 10.1016/S2666-5247(23)00344-0. Epub 2023 Nov 23. Lancet Microbe. 2024. PMID: 38008103 Free article. No abstract available.
Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.
Loriot Y, Necchi A, Park SH, Garcia-Donas J, Huddart R, Burgess E, Fleming M, Rezazadeh A, Mellado B, Varlamov S, Joshi M, Duran I, Tagawa ST, Zakharia Y, Zhong B, Stuyckens K, Santiago-Walker A, De Porre P, O'Hagan A, Avadhani A, Siefker-Radtke AO; BLC2001 Study Group. Loriot Y, et al. N Engl J Med. 2019 Jul 25;381(4):338-348. doi: 10.1056/NEJMoa1817323. N Engl J Med. 2019. PMID: 31340094 Clinical Trial.
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.
Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Choueiri TK, Gurney H, Donskov F, Bono P, Wagstaff J, Gauler TC, Ueda T, Tomita Y, Schutz FA, Kollmannsberger C, Larkin J, Ravaud A, Simon JS, Xu LA, Waxman IM, Sharma P; CheckMate 025 Investigators. Motzer RJ, et al. N Engl J Med. 2015 Nov 5;373(19):1803-13. doi: 10.1056/NEJMoa1510665. Epub 2015 Sep 25. N Engl J Med. 2015. PMID: 26406148 Free PMC article. Clinical Trial.
Mycoplasma pneumoniae beyond the COVID-19 pandemic: where is it?
Meyer Sauteur PM, Chalker VJ, Berger C, Nir-Paz R, Beeton ML; ESGMAC and the ESGMAC–MyCOVID study group. Meyer Sauteur PM, et al. Lancet Microbe. 2022 Dec;3(12):e897. doi: 10.1016/S2666-5247(22)00190-2. Epub 2022 Aug 11. Lancet Microbe. 2022. PMID: 35964636 Free PMC article. No abstract available.
Mycoplasma pneumoniae detections before and during the COVID-19 pandemic: results of a global survey, 2017 to 2021.
Meyer Sauteur PM, Beeton ML, Uldum SA, Bossuyt N, Vermeulen M, Loens K, Pereyre S, Bébéar C, Keše D, Day J, Afshar B, Chalker VJ, Greub G, Nir-Paz R, Dumke R; ESGMAC–MyCOVID Study Team. Meyer Sauteur PM, et al. Euro Surveill. 2022 May;27(19):2100746. doi: 10.2807/1560-7917.ES.2022.27.19.2100746. Euro Surveill. 2022. PMID: 35551702 Free PMC article.
Pneumonia outbreaks due to re-emergence of Mycoplasma pneumoniae.
Meyer Sauteur PM, Beeton ML; European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Mycoplasma and Chlamydia Infections (ESGMAC), and the ESGMAC Mycoplasma pneumoniae Surveillance (MAPS) study group. Meyer Sauteur PM, et al. Lancet Microbe. 2024 Jun;5(6):e514. doi: 10.1016/S2666-5247(23)00406-8. Epub 2024 Feb 8. Lancet Microbe. 2024. PMID: 38342111 Free article. No abstract available.
Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study.
Siefker-Radtke AO, Necchi A, Park SH, García-Donas J, Huddart RA, Burgess EF, Fleming MT, Rezazadeh Kalebasty A, Mellado B, Varlamov S, Joshi M, Duran I, Tagawa ST, Zakharia Y, Akapame S, Santiago-Walker AE, Monga M, O'Hagan A, Loriot Y; BLC2001 Study Group. Siefker-Radtke AO, et al. Lancet Oncol. 2022 Feb;23(2):248-258. doi: 10.1016/S1470-2045(21)00660-4. Epub 2022 Jan 11. Lancet Oncol. 2022. PMID: 35030333 Clinical Trial.
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial.
Powles T, van der Heijden MS, Castellano D, Galsky MD, Loriot Y, Petrylak DP, Ogawa O, Park SH, Lee JL, De Giorgi U, Bögemann M, Bamias A, Eigl BJ, Gurney H, Mukherjee SD, Fradet Y, Skoneczna I, Tsiatas M, Novikov A, Suárez C, Fay AP, Duran I, Necchi A, Wildsmith S, He P, Angra N, Gupta AK, Levin W, Bellmunt J; DANUBE study investigators. Powles T, et al. Lancet Oncol. 2020 Dec;21(12):1574-1588. doi: 10.1016/S1470-2045(20)30541-6. Epub 2020 Sep 21. Lancet Oncol. 2020. PMID: 32971005 Clinical Trial.
116 results